Latest Weather Blog
Gov't watchdog: many gaps in FDA's oversight of drug safety
WASHINGTON - The Food and Drug Administration is working hard to speed up reviews of new drugs, yet often fails to keep track of safety issues with those medicines once they reach patients, according to government investigators.
A new Government Accountability Office report outlines a host of shortcomings in FDA's system for tracking drug safety, including incomplete, outdated and inaccurate information.
The new findings are significant because FDA leadership have stressed the speed and efficiency with which agency scientists approve experimental drugs. Last year the agency approved 45 first-of-a-kind drugs, the highest number in 19 years. More than half received some form of specialized review to speed or streamline their review.
But the GAO says the agency often fails to keep track the follow-up studies required for these high-priority drugs.
Desktop NewsClick to open Continuous News in a sidebar that updates in real-time.
'We were set up for failure:' White Castle PD runs out of...
One injured in shooting off Chippewa Street Wednesday morning
Police identify 69-year-old shot, killed off Scenic Highway early Wednesday
Baker School Board approves teacher raises during Tuesday evening meeting
New bill adds option to donate bone marrow to state registration
LSU blasts 4 homers in 13-7 win over Oregon State to advance...
LSU baseball prepares for NCAA Regional play
LSU, Tulane to meet in first round of Baton Rouge Regional as...
LSU president reminisces during team trip to DC
Southern baseball sweeps Arkansas-Pine Bluff to finish out regular season